OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more
OmniAb Inc. (OABI) - Total Liabilities
Latest total liabilities as of September 2025: $32.25 Million USD
Based on the latest financial reports, OmniAb Inc. (OABI) has total liabilities worth $32.25 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OmniAb Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OmniAb Inc. Competitors by Total Liabilities
The table below lists competitors of OmniAb Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yingde Greatchem Chemicals Co. Ltd. A
SHE:300804
|
China | CN¥759.74 Million |
|
Mi Technovation Berhad
PINK:MITNF
|
USA | $37.73 Million |
|
Shengtak New Material Co Ltd
SHE:300881
|
China | CN¥2.11 Billion |
|
Shandong Huapeng Glass Co Ltd
SHG:603021
|
China | CN¥1.60 Billion |
|
Pharmagest Interactive
LSE:0R9T
|
UK | €171.66 Million |
|
Utah Medical Products Inc
NASDAQ:UTMD
|
USA | $3.27 Million |
|
Jack In The Box Inc
NASDAQ:JACK
|
USA | $3.53 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down OmniAb Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OmniAb Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OmniAb Inc. (2019–2024)
The table below shows the annual total liabilities of OmniAb Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.94 Million | -37.43% |
| 2023-12-31 | $60.64 Million | -24.05% |
| 2022-12-31 | $79.84 Million | +13.80% |
| 2021-12-31 | $70.16 Million | +17.24% |
| 2020-12-31 | $59.84 Million | +35.59% |
| 2019-12-31 | $44.13 Million | -- |